FDA Lays Out Rules For Early Study Of Higher-Risk Devices

Law360, New York (October 02, 2013, 2:56 PM ET) -- The U.S. Food and Drug Administration on Tuesday laid out new expectations for early clinical studies of higher-risk medical devices, describing a litany of conditions manufacturers must meet before such analyses are performed.

The 40-page guidance document covers investigational device exemptions that allow trials of unapproved products and applies only to so-called early feasibility studies, which tend to occur before device design has been finalized and involve a small group of 10 or fewer human subjects.

While many of the rules surrounding IDEs are contained in...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required